歯科医院長mabo400のブログ

Re-infection of the new corona has been confirmed. Vaccine development accelerated, but efficacy questioned.

 
この記事を書いている人 - WRITER -

As one of my patients who is a medical professional said, there’s no silver bullet for the common cold. The new corona is also a cold too. Neither Avigan nor Remdecivir is a poof. If there was a vaccine for the common cold that could be made, it would have been made long ago. The fact that there still isn’t one.

I’ve heard of a patient who may have been infected with the corona who have had a high fever for four days, and even after they’ve been cured, they are still suffering various after-effects, including pain in their lungs and pain in their hands and toes. Probably a symptom of thrombosis.

The government seems to be trying to remove the new type of corona from the list of designated infectious diseases, perhaps because it has become too much of a bother.
New corona treatment will no longer be publicly funded (no co-payments).

Be careful!

To quote from here…

 It’s cold water for the development of a vaccine for the new corona that’s on the horizon – and it’s cold water. A Hong Kong man, 33, who recovered from a corona infection, re-infected himself four and a half months later, the University of Hong Kong research team said on Thursday. Re-infection has been suspected in the past, but this is the first time in the world that this has been proven.

 The man was first found to be infected in March, and after two weeks of treatment he tested negative and was discharged from the hospital. However, when he returned to Hong Kong from Spain via the U.K. between the 6th and 15th of this month, he found out that he had been infected for the second time and the genetic sequence was different from the first. The man was released from the hospital on March 21 without symptoms.

 The team pointed out that the antibodies produced by the infection “diminish over time”, and the duration of the antibodies is about several months. The duration of the antibodies is thought to be a few months. Like the flu, annual vaccinations may be required. Even if antibodies from the first infection remain, if the patient is re-infected due to a difference in genetic sequence, there is a possibility that many different vaccines will be needed.

 Excessive expectations have been placed on the vaccine, but it may not be a “trump card”. Moreover, the side effects are of great concern.

 Dr. Hideomi Nakahara, headmaster of the Seibu Gakuen School of Medicine and Technology in Tokyo, says: “Vaccines administered to healthy people are not a good idea.

“Vaccines administered to healthy people must be safer than the drugs used to treat patients. If it is administered incorrectly, it may actually worsen the condition of healthy people.

Duration of antibodies for several months

 In animal studies of the development of a vaccine for severe acute respiratory syndrome (SARS), there were cases where the vaccination produced antibodies, but instead worsened the symptoms. Furthermore, it generally takes five to ten years for a vaccine to become commercially available. We are aiming for early commercialization of the corona vaccine using the latest technology that uses genetic information, but this is a technology that has never been used for any other disease. There are also concerns about completely unpredictable side effects.

The incentive for early development is particularly high in Japan, where the Tokyo Olympics are coming up next year. The Japanese government is desperate to make sure that companies are compensated for any damage caused by the side effects of the vaccine.

It’s dangerous to try to develop a vaccine in time for next year’s Tokyo Olympics,” he said. We must develop the vaccine with a great deal of caution.

 Antibodies from vaccines given at the risk of side effects are not worth the risk of sustaining them for a few months.

https://www.nikkan-gendai.com/articles/view/life/277832

この記事を書いている人 - WRITER -

- Comments -

メールアドレスが公開されることはありません。

Copyright© I歯科医院の高楊枝通信。 , 2020 All Rights Reserved.